Clinical trials: cyclosporine
End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD)
Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)
This is a 2-year, randomized, multicenter, open-label, 2-arm study evaluating the graft function of everolimus and reduced CNI versus MPA and standard CNI in adult de novo renal transplant recipients.
- Conditions
- End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis, Renal Replacement Therapy
- Trial name
- TRANSFORM (NCT01950819)
- Testing
- Induction therapy, Corticosteroids, EVR+rCNI
- Where
- 184 sites in United States, Argentina and 40 more
- Volunteers
- 2,037 people
- Sponsor
- Novartis Pharmaceuticals
Heart Transplantation, Renal Failure
Rapamycin Use in Calcineurin Inhibitor (CNI)-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation
Clinical Problem: Renal insufficiency after heart transplantation caused by cyclosporine medication was addressed. Current therapeutic approaches include cyclosporine reduction or discontinuation.
- Trial name
- NCT00123331
- Testing
- Cyclosporine discontinuation, Rapamycin medication
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Heidelberg University
Leprosy
Ciclosporin in the Management of Steroid Resistant Type 1 Reactions in Leprosy
Study 1B: Ciclosporin in the management of steroid resistant Type 1 Reactions in Leprosy Objective: A pilot study assessing the efficacy and safety of Ciclosporin as a second -line drug in patients with Type 1 Reactions who have…
- Trial name
- NCT00919451
- Testing
- ciclosporin
- Where
- Ethiopia
- Volunteers
- 16 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Kidney Transplantation
Study Comparing Graft Function in Renal Allograft Recepients Receiving Reduced or Standard Dose CsA With Sirolimus
This study evaluated renal graft function (based on calcuated creatinine clearance) 12 months after transplantation in patients receiving either a regimen of reduced dose or standard dose cyclosporine in combination with…
- Trial name
- NCT00518375
- Testing
- Rapamune® (Sirolimus), Neoral® (Cyclosporine), Corticosteroids
- Volunteers
- 250 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Myelodysplastic Syndromes
Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Myelodysplastic Syndromes
The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSCs) derived from human umbilical cord/placenta at a dose of 1.0E+6 MSC/kg on the subjects for refractory anemia (RA) and refractory…
- Trial name
- NCT01129739
- Testing
- Human umbilical cord-derived MSCs, cyclosporine A (CsA)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shandong University
Behçet Disease, Uveitis
Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis
Brief summary: This study compares the long-term efficacy and safety of interferon (IFN) α2a and cyclosporine (cyclosporin A, CsA) following suppression of acute attack by high-dose oral glucocorticosteroid in patients with…
- Trial name
- NCT03209219
- Testing
- Interferon Alfa-2A, Cyclosporine Pill
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Peking Union Medical College Hospital
Prostate Cancer
Monoclonal Antibody Therapy Plus Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00009750
- Testing
- filgrastim, monoclonal antibody m170, cyclosporine
- Where
- United States
- Sponsor
- University of California, Davis
Psoriasis
A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies
This is a Phase IIIb/IV, open label, multicentre study of efalizumab (anti cluster of differentiation [CD] 11a recombinant human monoclonal antibody) in participants with moderate to severe plaque psoriasis who have failed to…
- Trial name
- NCT00249808
- Testing
- Efalizumab - anti-CD11a recombinant human monoclonal antibody
- Where
- United Kingdom
- Volunteers
- 1,266 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Kidney Transplantation
Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids
The 12 Month Core Study (CRAD001A1202) was designed to evaluate the efficacy and safety comparing concentration-controlled everolimus (1.5 mg/day starting dose) with reduced dose cyclosporine and corticosteroids versus 2 g/day…
- Trial name
- NCT00658320
- Testing
- Everolimus, Mycophenolate mofetil (MMF), Basiliximab
- Where
- Japan
- Volunteers
- 122 people
- Sponsor
- Novartis
Systemic Lupus Erythematosus
Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)
The purpose of this study is to initially access the safety and effectivity of RC18 combined with standard treatment and Placebo combined with standard therapy in subjects with Moderate to severe SLE, Besides ,to provide dose…
- Trial name
- NCT02885610
- Testing
- RC18 80 mg plus standard therapy, RC18 160 mg plus standard therapy, RC18 240 mg plus standard therapy
- Where
- China
- Volunteers
- 249 people
- Sponsor
- RemeGen Co., Ltd.
Membranoproliferative Glomerulonephritis
Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis
Type I membranoproliferative glomerulonephritis (MPGN) is a relatively uncommon glomerular disease, constituting 1.8% of renal biopsies performed in Rochester, minnesota, United States of America, at the Mayo Clinic, between 1993…
- Trial name
- NCT03180723
- Testing
- Rituximab, Cyclosporin
- Volunteers
- 30 people
- Sponsor
- Assiut University
Renal Function
Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients
This study is designed to evaluate if early conversion to everolimus from cyclosporine in de novo renal transplant recipients can improve long-term renal function and slow down the progression of chronic allograft nephropathy
- Trial name
- NCT00634920
- Testing
- everolimus, cyclosporine A, Enteric Coated Mycophenolate Sodium (EC-MPS)
- Where
- 8 sites in Denmark, Norway and 1 more
- Volunteers
- 204 people
- Sponsor
- Novartis Pharmaceuticals
Liver Transplantation
Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant
This two-arm study will assess the efficacy and safety of a long-term calcineurin inhibitor-free maintenance regimen with CellCept and sirolimus in recipients of an orthotropic liver transplant.
- Trial name
- NCT00118742
- Testing
- mycophenolate mofetil [CellCept], Tacrolimus, Cyclosporine
- Where
- 46 sites in United States, Canada
- Volunteers
- 293 people
- Sponsor
- Hoffmann-La Roche
Acute Myeloid Leukemia, Myelodysplastic Syndromes
IFN-α in Relapse Prevention.
To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) by flow cytometry…
- Trial name
- NCT07449286
- Testing
- IFN-α
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Venous Thromboembolism, Pharmacokinetics
Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus
This study aims to evaluate the pharmacokinetics (PK) of apixaban when co-administered with cyclosporine and tacrolimus in healthy volunteers.
- Conditions
- Venous Thromboembolism, Pharmacokinetics, Healthy
- Trial name
- ACT (NCT03083782)
- Testing
- Apixaban alone, Cyclosporine, Tacrolimus
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Corneal Neovascularization, Corneal Graft Failure
Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions
The purpose of the study is to test the investigational drug Gamunex-C on the growth of blood vessels over the cornea. This study is being conducted by Dr. Balamurali Ambati at the Moran Eye Center at the University of Utah.
- Conditions
- Corneal Neovascularization, Corneal Graft Failure, Anterior Segment Inflammation
- Trial name
- NCT02042027
- Testing
- Gamunex-C
- Where
- United States
- Sponsor
- University of Utah
Leukemia Lymphoblastic, Acute, Acute Myeloid Leukemia
Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.
Stem cell transplant is an important therapeutic option for pediatric patients with relapsed or refractory leukemia. Although, full myeloablative transplants are widely used for patients with acute leukemia, myeloablative…
- Conditions
- Leukemia Lymphoblastic, Acute, Acute Myeloid Leukemia, Neoplasm Recurrent
- Trial name
- NCT01041508
- Testing
- Clofarabine, Total Body Irradiation, Stem Cell Transplantation
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Myelofibrosis
Haplo-HSCT for Myelofibrosis
Myelofibrosis (MF) is a myeloproliferative neoplasm causing bone marrow failure and high risk of leukemia transformation. JAK2 inhibitors improve symptoms but do not cure MF.
- Trial name
- HHM (NCT06674382)
- Testing
- Haploidentical hematopoietic stem cell transplantation
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Peking University People's Hospital
Dry Eye Syndromes
A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.
A prospective, randomized, placebo and active comparator controlled study of CP-690,550 in subjects with dry eye.
- Trial name
- NCT00784719
- Testing
- CP-690,550, Cyclosporine, CP-690,550 Vehicle
- Where
- 27 sites in United States
- Volunteers
- 327 people
- Sponsor
- Pfizer
COVID, Kidney Transplant; Complications
Maintenance Versus Reduction of Immunosuppression for Renal Transplant Patients Hospitalized With COVID-19 Disease
This will be a randomized trial of maintenance versus reduction in immunosuppression in adult patients (age >18 years old) with functioning renal transplants admitted to hospital with confirmed COVID-19 disease.
- Conditions
- COVID, Kidney Transplant; Complications, Immunosuppression
- Trial name
- NCT04420364
- Testing
- Maintenance or reduction of immunosuppression
- Sponsor
- Brigham and Women's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.